Two Oxford haemophilia specialists have £520,000 from the NIHR for a UK trial of hyaluronic acid injections for ankle arthritis. Patients asked for it in 2018.

Two specialists at the Oxford Haemophilia and Thrombosis Centre have been awarded £520,000 to run a national trial of a joint injection for ankle arthritis caused by haemophilia. The money comes from the National Institute for Health and Care Research (NIHR) Research for Patient Benefit programme. Oxford University Hospitals NHS Foundation Trust (OUH) announced the award on 12 November. (OUH, 12 November 2026)

Overview

  • Who: Dr Nicola Curry, Consultant Haematologist, and Steph Taylor, Senior Haemophilia Physiotherapist, at the Oxford Haemophilia and Thrombosis Centre.
  • What: a placebo-controlled trial across the UK of hyaluronic acid injected into the ankle, sometimes called “liquid cartilage”.
  • Funding: £520,000 from the NIHR Research for Patient Benefit programme.
  • Why: three in five people with haemophilia have ankle joint damage by the age of 30, and there are few good treatments.

The problem it is trying to solve

People with haemophilia bleed repeatedly into their joints. Over time this causes permanent damage, known as haemophilic arthropathy. The ankle is the joint most often affected.

OUH says the pain from this kind of ankle arthritis affects every part of a patient’s life. Patients with haemophilia have particular needs, so many treatments used for ordinary arthritis are not straightforward for them.

The trial will test whether injecting hyaluronic acid into the ankle improves:

  • pain
  • how well the ankle works
  • overall quality of life

Hyaluronic acid occurs naturally in many joints. Injections of it are sometimes used to treat knee pain from osteoarthritis.

Built on an Oxford pilot

The team ran a pilot study in 2023, sponsored by OUH. It showed early signs that hyaluronic acid reduced pain and improved ankle function. The trust says that pilot was pivotal in winning the new money.

The new study will be much larger and will run at several centres across the UK. Some patients will receive a placebo, so the team can say definitively whether the injection works.

Dr Curry and Steph Taylor also work in the Nuffield Division of Clinical Laboratory Sciences, part of the Radcliffe Department of Medicine. They will run the trial with the Surgical Intervention Trials Unit in the Nuffield Department of Surgical Sciences, and with the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.

Dr Curry said:

“Steph and I are delighted to have support from the NIHR for this trial. We were asked by our patients in 2018 to investigate better treatments for ankle arthropathy. To be able to deliver this national trial is exciting, as we will be able to provide important answers to our patients. It has been, and will continue to be, a truly patient-designed clinical trial.

“Our study has the potential to open new avenues for routine therapy for our haemophilia patient group.”

Where the centre is

The Oxford Haemophilia and Thrombosis Centre is one of the largest haemophilia comprehensive care centres in the UK. It moved from the Churchill Hospital to the Nuffield Orthopaedic Centre in Headington in March 2022. (OUH, 7 October 2022)

What it means for you

  • No recruitment has been announced yet. OUH has not published start dates or how patients will be chosen. Patients of the centre can ask their haemophilia team about it.
  • It is a trial, not a new routine treatment. The point of the placebo design is to find out whether the injections genuinely help before they are offered more widely.
  • The NHS has background on haemophilia. The Haemophilia Society supports patients and families.